A new trading day began on Tuesday, with Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) stock price down -11.50% from the previous day of trading, before settling in for the closing price of $13.57. CNTA’s price has ranged from $7.75 to $19.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. Meanwhile, its annual earnings per share averaged 29.13%. With a float of $84.29 million, this company’s outstanding shares have now reached $132.63 million.
Let’s look at the performance matrix of the company that is accounted for 77 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 36.45%, while institutional ownership is 55.07%. The most recent insider transaction that took place on May 01 ’25, was worth 4,354. In this transaction General Counsel of this company sold 311 shares at a rate of $14.00, taking the stock ownership to the 105,386 shares. Before that another transaction happened on Apr 25 ’25, when Company’s General Counsel sold 3,609 for $14.00, making the entire transaction worth $50,526. This insider now owns 105,386 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 29.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.48% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Here are Centessa Pharmaceuticals plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.99, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) saw its 5-day average volume 0.69 million, a negative change from its year-to-date volume of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 40.03%. Additionally, its Average True Range was 0.98.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 25.40%, which indicates a significant increase from 17.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.30% in the past 14 days, which was lower than the 64.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.31, while its 200-day Moving Average is $15.10. Nevertheless, the first resistance level for the watch stands at $13.01 in the near term. At $14.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.60. If the price goes on to break the first support level at $11.42, it is likely to go to the next support level at $10.82. Assuming the price breaks the second support level, the third support level stands at $9.83.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
With a market capitalization of 1.59 billion, the company has a total of 133,184K Shares Outstanding. Currently, annual sales are 0 K while annual income is -235,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -111,330 K.
